Clinical strategies for management of abnormal uterine bleeding: hormonal and nonhormonal interventions in women at risk for venous thromboembolism DOI
Caroline S. Kwon, Harish Eswaran,

Erin T. Carey

et al.

Current Opinion in Obstetrics & Gynecology, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Purpose of review This explores the medical management abnormal uterine bleeding (AUB) in women at risk for venous thromboembolism (VTE), with a focus on six key principles to consider when initiating hormonal therapies this patient population. Case studies are used illustrate these practice, emphasizing importance assessing patient’s thrombotic and selecting appropriate effectively manage AUB while minimizing VTE. Recent findings While estrogen certain high-dose progestins known elevate VTE risk, evidence suggests that progestin-only formulations lower-dose may not significantly increase even vulnerable populations. Antifibrinolytic agents such as tranexamic acid effective reducing menstrual blood loss without thromboembolic complications. Summary There is wide variability risks associated various nonhormonal available managing AUB. A thorough evaluation factors preferences essential events.

Language: Английский

Disparities in menstrual bleeding management during acute venous thromboembolism treatment: A review of UK practice and a call for clinical studies DOI Creative Commons
Eman Hassan,

David Sutton,

Richard J. Buka

et al.

Thrombosis Research, Journal Year: 2025, Volume and Issue: 247, P. 109258 - 109258

Published: Jan. 14, 2025

Language: Английский

Citations

1
Ferritina antes que hemoglobina. Impacto del sangrado uterino anormal en la calidad de vida DOI

Diego Vela,

Francisco Bernardez,

Cecilia Braxs

et al.

Clínica e Investigación en Ginecología y Obstetricia, Journal Year: 2025, Volume and Issue: unknown, P. 101015 - 101015

Published: Feb. 1, 2025

Citations

0
Ferritin before hemoglobin: Impact of abnormal uterine bleeding on quality of life DOI Creative Commons

Daniela Vela,

Francisco Bernardez,

Cecilia Braxs

et al.

Journal of Endometriosis and Uterine Disorders, Journal Year: 2025, Volume and Issue: 9, P. 100098 - 100098

Published: Feb. 11, 2025

Language: Английский

Citations

0
Tranexamic Acid for Postpartum Haemorrhage in Low-, Middle-, and High-Income Countries: An Integrative Review Aligned with the WHO PPH Roadmap (2023–2030) DOI Creative Commons
Victor Abiola Adepoju, Qorinah Estiningtyas Sakilah Adnani,

Marius Olusola Adeniyi

et al.

Women, Journal Year: 2025, Volume and Issue: 5(1), P. 10 - 10

Published: March 14, 2025

The World Health Organization recommends Tranexamic acid (TXA) in the treatment of postpartum haemorrhage (PPH) as part PPH care bundle. We conducted integrative review 36 studies from three databases namely PubMed, Google Scholar, and Dimensions. followed PRISMA guidelines evaluated clinical efficacy TXA, prophylactic use, cost-effectiveness, alternative administration routes, real-world implementation challenges facilitators. found that early TXA within hours onset significantly reduces maternal mortality by 31%. Despite concerns about thrombosis, pooled data large-scale cohorts demonstrate minimal thromboembolic risk which reinforces safety profile TXA. However, WOMAN-2 trial revealed no significant benefit women with moderate-to-severe anaemia highlights necessity for patient-specific protocols. Economic evaluations reveal integrating into national requires a modest budget increase (approximately 2.3%) but promises substantial cost savings through reduced surgeries hospital stays. While intravenous remains recommended route WHO, emerging evidence supports intramuscular topical is crucial rural or primary-care settings lacking facilities. Yet, questions bioavailability rapid haemostatic persist, awaiting outcomes ongoing trials such I’M WOMAN, currently recruiting aged 18 years five countries results anticipated late 2025. Significant barriers to widespread adoption include limited healthcare provider training, lack budgetary allocation government cultural misconceptions associating “dangerous clotting” some settings. Successful initiatives, like China’s Strategies Tools Enhance Parturient Safety (STEPS) programme, illustrate how enhanced perinatal bundles, interdisciplinary team continuous monitoring using statistical process control (SPC) tools can overcome these obstacles. To accelerate progress towards reducing preventable deaths globally, future research must address variable effectiveness when used prophylaxis, clarify subpopulations most likely benefit, rigorously assess routes administration.

Language: Английский

Citations

0
Clinical strategies for management of abnormal uterine bleeding: hormonal and nonhormonal interventions in women at risk for venous thromboembolism DOI
Caroline S. Kwon, Harish Eswaran,

Erin T. Carey

et al.

Current Opinion in Obstetrics & Gynecology, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Purpose of review This explores the medical management abnormal uterine bleeding (AUB) in women at risk for venous thromboembolism (VTE), with a focus on six key principles to consider when initiating hormonal therapies this patient population. Case studies are used illustrate these practice, emphasizing importance assessing patient’s thrombotic and selecting appropriate effectively manage AUB while minimizing VTE. Recent findings While estrogen certain high-dose progestins known elevate VTE risk, evidence suggests that progestin-only formulations lower-dose may not significantly increase even vulnerable populations. Antifibrinolytic agents such as tranexamic acid effective reducing menstrual blood loss without thromboembolic complications. Summary There is wide variability risks associated various nonhormonal available managing AUB. A thorough evaluation factors preferences essential events.

Language: Английский

Citations

0